Flavopiridol (Synonyms: HMR-1275; Alvocidib; L86-8275)

Name: Flavopiridol
Brand: MedChemExpress
SKU: HY-10005
Rating: 5.0 (52 reviews)

Cat. No.: HY-10005 Purity: 99.68%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

For research use only. We do not sell to patients.

CAS No. : 146426-40-6

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 52 publication(s) in Google Scholar

Other Forms of Flavopiridol:

Flavopiridol Hydrochloride In-stock
Flavopiridol (Standard) Get quote

52 Publications Citing Use of MCE Flavopiridol

Cell Imaging/Staining

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

IHC

Flow Cytometry

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Nature. 2025 Aug;644(8076):557-566. [Abstract]; Nucleolar morphology (IF for RPA194, FBL, and NPM1 for FC, DFC and GC) in DMSO (-FVP) and after 30-90 min of 2 μM FVP (Flavopiridol) treatment.

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Nature. 2024 Apr;628(8007):408-415. [Abstract]; Immunoblotting showing CDK9, Ser2P and β-Actin protein levels in macrophages treated with either DMSO or Flavopiridol (10 μM) for 30 min. n = 3 independent experiments.

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155.; Flavopiridol (Flav; 0-1 μg/mL; 24 h). MTT assay-derived curves of PF, Flav, PF + Flav and PNM in 4T1 cells after 24 h of treatment.

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155.; Flavopiridol (Flav; 5 mg/kg; i.v.). Schedule of establishment of the 4T1 tumor-bearing mouse model and different treatments. Average tumor growth curves of the mice treated with PBS, PF, Flav, PF + Flav and PNM.

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155.; Flavopiridol (Flav; 5 mg/kg; i.v.). Representative pictures of HE staining and Ki-67 staining in tumor sections of different groups.

: Flavopiridol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155.; Flavopiridol (Flav; 5 mg/kg; i.v.). Representative flow cytometric plots of CD8⁺ T cells in tumors.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

IC₅₀ & Target^[3]

CDK1/Cyc B1

30 nM (IC₅₀)

CDK2/Cyc E

170 nM (IC₅₀)

CDK4/Cyc D1

100 nM (IC₅₀)

MAP

19000 nM (IC₅₀)

PKC

14000 nM (IC₅₀)

EGFR

22000 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of A431 human squamous cell carcinoma cell proliferation Inhibition of A431 human squamous cell carcinoma cell proliferation	[PMID: 12190313]
A2780	GI₅₀	0.023 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.029 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.031 μM Compound: Flavopiridol	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 23301767]
A2780	GI₅₀	0.064 μM Compound: Flavopiridol	Growth inhibition of human A2780 cells after 48 hrs by MTT assay Growth inhibition of human A2780 cells after 48 hrs by MTT assay	[PMID: 33581551]
A2780	IC₅₀	0.038 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.056 μM Compound: Flavopiridol	Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	0.071 μM Compound: 1 (flavopiridol)	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay	[PMID: 15027863]
A2780	IC₅₀	0.078 μM Compound: Flavopiridol	Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation	[PMID: 12190313]
A2780	IC₅₀	15 μM Compound: 1 (flavopiridol)	Inhibition of A2780 cell clonogenic assay Inhibition of A2780 cell clonogenic assay	[PMID: 11063609]
A2780	IC₅₀	71 nM Compound: 1	Cytotoxic effect on human ovarian (A2780) cancer cell line Cytotoxic effect on human ovarian (A2780) cancer cell line	[PMID: 15125971]
A549	CC₅₀	> 100 μM Compound: 11; L86-8275, HMR1275	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33539089]
A549	GI₅₀	0.14 μM Compound: FVP	Antiproliferative activity against human A549 cells after 3 days by SRB method Antiproliferative activity against human A549 cells after 3 days by SRB method	[PMID: 25914804]
A549	GI₅₀	0.145 μM Compound: Flavopiridol	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 33581551]
A549	IC₅₀	0.096 μM Compound: Flavopiridol	Inhibition of A549 human lung carcinoma cell proliferation Inhibition of A549 human lung carcinoma cell proliferation	[PMID: 12190313]
A549	IC₅₀	0.1 μM Compound: Flavopiridol	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
ABAE	IC₅₀	0.045 μM Compound: Flavopiridol	Inhibition of ABAE human fibroblast cell proliferation Inhibition of ABAE human fibroblast cell proliferation	[PMID: 12190313]
BJ	EC₅₀	> 86.2069 μM Compound: 4	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
CCRF-CEM	IC₅₀	0.052 μM Compound: Flavopiridol	Inhibition of CCRF-CEM human leukemia cell proliferation Inhibition of CCRF-CEM human leukemia cell proliferation	[PMID: 12190313]
CNE-2	IC₅₀	0.12 μM Compound: Flavopiridol	Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human CNE-2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
COLO 205	EC₅₀	> 20 μM Compound: Chemical Probe: Flavopiridol	Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry Cell cycle arrest in human COLO 205 cells assessed as accumulation of cells at G1 phase by measuring increase in 2N DNA content measured after 24 hrs by propidium iodide staining based laser-scanning fluorescence cytometry	[PMID: 24919854]
CWR22R	IC₅₀	0.24 μM Compound: FP	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 37672930]
Caco-2	IC₅₀	0.086 μM Compound: Flavopiridol	Inhibition of CACO-2 human colon carcinoma cell proliferation Inhibition of CACO-2 human colon carcinoma cell proliferation	[PMID: 12190313]
DU-145	GI₅₀	0.15 μM Compound: FVP	Antiproliferative activity against human DU145 cells after 3 days by SRB method Antiproliferative activity against human DU145 cells after 3 days by SRB method	[PMID: 25914804]
HCT-116	EC₅₀	0.034 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 10% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum Antiproliferative activity against human HCT116 cells after 72 hrs by Celltiter-Glo reagent based assay in presence of 0.625% fetal bovine serum	[PMID: 26985305]
HCT-116	EC₅₀	0.059 μM Compound: Flavopiridol	Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition in presence of 0.625% FBS after 72 hrs	[PMID: 27326333]
HCT-116	GI₅₀	0.056 μM Compound: Flavopiridol	Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay Growth inhibition of human HCT-116 cells after 48 hrs by MTT assay	[PMID: 33581551]
HCT-116	IC₅₀	0.017 μM Compound: Flavopiridol	Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation Inhibition of HCT116 / VP35 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.018 μM Compound: Flavopiridol	Inhibition of HCT116 human colon carcinoma cell proliferation Inhibition of HCT116 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.021 μM Compound: Flavopiridol	Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation Inhibition of HCT116 / VM46 human colon carcinoma cell proliferation	[PMID: 12190313]
HCT-116	IC₅₀	0.03 μM Compound: Flavopiridol	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HCT-116	IC₅₀	13 μM Compound: 1 (flavopiridol)	Inhibition of HCT116 cell clonogenic assay Inhibition of HCT116 cell clonogenic assay	[PMID: 11063609]
HCT-116	IC₅₀	20 nM Compound: Alvocidib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
HL-60	IC₅₀	0.046 μM Compound: Flavopiridol	Inhibition of HL60 human leukemia cell proliferation Inhibition of HL60 human leukemia cell proliferation	[PMID: 12190313]
HMEC-1	GI₅₀	0.061 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.062 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay	[PMID: 23301767]
HMEC-1	GI₅₀	0.066 μM Compound: Flavopiridol	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay	[PMID: 23301767]
HS27	IC₅₀	0.051 μM Compound: Flavopiridol	Inhibition of Hs 27 human fibroblast cell proliferation Inhibition of Hs 27 human fibroblast cell proliferation	[PMID: 12190313]
HT-29	GI₅₀	0.131 μM Compound: Flavopiridol	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 33581551]
HeLa	CC₅₀	0.12 μM Compound: 8; Alvocidib	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 27171036]
HeLa	GI₅₀	0.043 μM Compound: Flavopiridol	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 33581551]
HeLa	IC₅₀	0.15 μM Compound: Flavopiridol	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
HepG2	EC₅₀	0.1464 μM Compound: 4	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
HepG2	IC₅₀	0.56 μM Compound: Flavopiridol	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
K562	IC₅₀	0.13 μM Compound: Flavopiridol	Inhibition of K562 human leukemia cell proliferation Inhibition of K562 human leukemia cell proliferation	[PMID: 12190313]
K562	IC₅₀	125 nM Compound: Alvocidib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
KB	GI₅₀	0.16 μM Compound: FVP	Antiproliferative activity against human KB cells after 3 days by SRB method Antiproliferative activity against human KB cells after 3 days by SRB method	[PMID: 25914804]
KOPN-8	EC₅₀	0.1926 μM Compound: 4	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
LNCaP	IC₅₀	0.016 μM Compound: Flavopiridol	Inhibition of LNCaP human prostate carcinoma cell proliferation Inhibition of LNCaP human prostate carcinoma cell proliferation	[PMID: 12190313]
LS174T	IC₅₀	0.065 μM Compound: Flavopiridol	Inhibition of LS174T human colon carcinoma cell proliferation Inhibition of LS174T human colon carcinoma cell proliferation	[PMID: 12190313]
LX-1	IC₅₀	0.075 μM Compound: Flavopiridol	Inhibition of LX-1 human lung carcinoma proliferation Inhibition of LX-1 human lung carcinoma proliferation	[PMID: 12190313]
M109	IC₅₀	0.08 μM Compound: Flavopiridol	Inhibition of M109 mouse lung carcinoma cell proliferation Inhibition of M109 mouse lung carcinoma cell proliferation	[PMID: 12190313]
MCF7	GI₅₀	0.092 μM Compound: Flavopiridol	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 33581551]
MCF7	IC₅₀	0.026 μM Compound: 1	Antiproliferative activity against MCF7 cells Antiproliferative activity against MCF7 cells	[PMID: 17123821]
MCF7	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of MCF-7 human breast carcinoma cell proliferation Inhibition of MCF-7 human breast carcinoma cell proliferation	[PMID: 12190313]
MCF7	IC₅₀	0.5 μM Compound: 1	Inhibition of MCF-7 tumor cell proliferation Inhibition of MCF-7 tumor cell proliferation	[PMID: 10843211]
MCF7	IC₅₀	0.71 μM Compound: Flavopiridol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-231	IC₅₀	0.06 μM Compound: Flavopiridol	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MDA-MB-468	GI₅₀	0.096 μM Compound: Flavopiridol	Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	GI₅₀	0.078 μM Compound: Flavopiridol	Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay Growth inhibition of human MIA PaCa-2 cells after 48 hrs by MTT assay	[PMID: 33581551]
MIA PaCa-2	IC₅₀	320 nM Compound: Alvocidib	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
MIA PaCa-2	IC₅₀	36 μM Compound: 1 (flavopiridol)	Inhibition of Mia PaCa-2 cell clonogenic assay Inhibition of Mia PaCa-2 cell clonogenic assay	[PMID: 11063609]
MIP	IC₅₀	0.12 μM Compound: Flavopiridol	Inhibition of MIP human colon carcinoma cell line Inhibition of MIP human colon carcinoma cell line	[PMID: 12190313]
MLF	IC₅₀	0.072 μM Compound: Flavopiridol	Inhibition of MLF mouse lung fibroblast cell proliferation Inhibition of MLF mouse lung fibroblast cell proliferation	[PMID: 12190313]
MOLM-13	IC₅₀	0.07 μM Compound: Flavopiridol	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK8 method	[PMID: 36087428]
MRC5	GI₅₀	0.028 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.039 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 23301767]
MRC5	GI₅₀	0.049 μM Compound: Flavopiridol	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 23301767]
MT4	EC₅₀	0.015 μM Compound: FVP	Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay Antiviral activity against Human immunodeficiency virus 1 NL 4-3 infected in MT4 cells measured on day 4 post infection by p24 assay	[PMID: 25914804]
MT4	IC₅₀	0.067 μM Compound: FVP	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 25914804]
MV4-11	IC₅₀	0.079 μM Compound: 1	Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay Growth inhibition of human MV4-11 cells incubated after 72 hrs by CTG- luminescence assay	[PMID: 34415148]
NCI-N87	IC₅₀	111 nM Compound: Alvocidib	Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
OVCAR-3	IC₅₀	0.054 μM Compound: Flavopiridol	Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation	[PMID: 12190313]
Oocyte	IC₅₀	0.2 μM Compound: Flavopiridol	Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes Inhibition of Cyclin-dependent kinase 1-cyclin B from M phase starfish (Marthasterias glacialis) oocytes	[PMID: 12593668]
Oocyte	IC₅₀	0.4 μM Compound: Flavopiridol (table 2 Page 6846)	Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes Inhibitory concentration against CDK1/Cyclin B complex from Marthasterias glacialis M-phase oocytes	[PMID: 16250643]
PC-3	IC₅₀	0.066 μM Compound: Flavopiridol	Inhibition of PC3 human prostate carcinoma cell proliferation Inhibition of PC3 human prostate carcinoma cell proliferation	[PMID: 12190313]
PC-3	IC₅₀	10 μM Compound: 1 (flavopiridol)	Inhibition of PC3 cell clonogenic assay Inhibition of PC3 cell clonogenic assay	[PMID: 11063609]
PC-3	IC₅₀	110 nM Compound: Alvocidib	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
RPMI-8226	IC₅₀	140 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay	[PMID: 19169685]
RPMI-8226	IC₅₀	394 nM Compound: Flavopiridol	Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay	[PMID: 19169685]
SEM	EC₅₀	0.2043 μM Compound: 4	Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
SK-BR-3	IC₅₀	0.077 μM Compound: Flavopiridol	Inhibition of SKBR-3 human breast carcinoma cell proliferation Inhibition of SKBR-3 human breast carcinoma cell proliferation	[PMID: 12190313]
SK-BR-3	IC₅₀	75 nM Compound: Alvocidib	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SK-OV-3	IC₅₀	0.22 μM Compound: Alvocidib	Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 32402934]
SUP-B15	EC₅₀	> 86.2069 μM Compound: 4	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Sf21	IC₅₀	395 nM Compound: 8; Alvocidib	Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged cyclin D3 expressed in sf21 cells using histone H1 substrate	[PMID: 27171036]
Sf9	IC₅₀	0.012 μM Compound: flavopiridol	Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells	[PMID: 17904366]
Sf9	IC₅₀	0.13 μM Compound: FVP	Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography Inhibition of CDK2/cyclin E1 (unknown origin) expressed in Sf9 insect cells using UlightCFFKNIVTPRTPPPSQGK-amide substrate after 15 mins by autoradiography	[PMID: 25914804]
Sf9	IC₅₀	2.5 nM Compound: 8; Alvocidib	Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis Inhibition of human His6-tagged CDK9/cyclin T1 expressed in baculovirus infected sf9 cells using GST-CTD as substrate after 10 mins in presence of [gamma-32P]ATP by SDS-PAGE analysis	[PMID: 27171036]
T-cell	IC₅₀	20 nM Compound: 1; L868275	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 35485642]
T-cell	IC₅₀	6 nM Compound: Flavopiridol	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 19169685]
UoC-B1	EC₅₀	0.2084 μM Compound: 4	Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]

In Vitro

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases^[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol^[2].
Flavopiridol (Alvocidib) also inhibits cyclin E1 and induces apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

401.84

Formula

C₂₁H₂₀ClNO₅

CAS No.

146426-40-6

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (82.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4886 mL	12.4428 mL	24.8855 mL
5 mM	0.4977 mL	2.4886 mL	4.9771 mL
10 mM	0.2489 mL	1.2443 mL	2.4886 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (stored under nitrogen). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.70%

Select Batch:

Data Sheet (281 KB) SDS (394 KB)

COA (255 KB) LCMS (406 KB)

Handling Instructions (2659 KB)

References

[1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. [Content Brief]

[2]. Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. [Content Brief]

[3]. Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. [Content Brief]

[4]. Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17(1):85. [Content Brief]

Cell Assay
^[1]

The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/NSC-187208 samples, NSC-187208 is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. [Content Brief]

[2]. Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. [Content Brief]

[3]. Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. [Content Brief]

[4]. Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17(1):85. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4886 mL	12.4428 mL	24.8855 mL	62.2138 mL
	5 mM	0.4977 mL	2.4886 mL	4.9771 mL	12.4428 mL
	10 mM	0.2489 mL	1.2443 mL	2.4886 mL	6.2214 mL
	15 mM	0.1659 mL	0.8295 mL	1.6590 mL	4.1476 mL
	20 mM	0.1244 mL	0.6221 mL	1.2443 mL	3.1107 mL
	25 mM	0.0995 mL	0.4977 mL	0.9954 mL	2.4886 mL
	30 mM	0.0830 mL	0.4148 mL	0.8295 mL	2.0738 mL
	40 mM	0.0622 mL	0.3111 mL	0.6221 mL	1.5553 mL
	50 mM	0.0498 mL	0.2489 mL	0.4977 mL	1.2443 mL
	60 mM	0.0415 mL	0.2074 mL	0.4148 mL	1.0369 mL
	80 mM	0.0311 mL	0.1555 mL	0.3111 mL	0.7777 mL

Flavopiridol Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Flavopiridol146426-40-6HMR-1275 Alvocidib L86-8275HMR1275HMR 1275CDKAutophagyHIVApoptosisCyclin dependent kinaseHuman immunodeficiency virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Flavopiridol (Synonyms: HMR-1275; Alvocidib; L86-8275)

Customer Review

Other Forms of Flavopiridol:

Flavopiridol Related Antibodies

52 Publications Citing Use of MCE Flavopiridol

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All HIV Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Flavopiridol Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Flavopiridol Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report